Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Developing a novel dengue vaccine 

Professor Arturo Reyes-Sandoval (Nuffield Department of Clinical Medicine) was awarded funding for his project to develop a new vaccine against dengue fever. Find out more. 

Modulating circadian rhythm disruption

Dr Sridhar Vasudevan (Department of Pharmacology) received funding to investigate a series of drugs which could be used to modulate and treat circadian rhythm disorders. Find out more. 

Developing slow-wave activity saturation as a marker of depth of anaesthesia 

Dr Katie Warnaby (Nuffield Department of Clinical Neurosciences) received funding to develop a new technique for measuring depth of anaesthesia in patients. Find out more. 


Further funded projects

  • Development of UGGT1 inhibitors as broad-spectrum antivirals: Zitzmann, Nicole. Biochemistry. £36,709
  • Development of an adeno-associated viral vectored immunoprophylactic strategy against blood-stage Plasmodium vivax Malaria: Bardelli, Martino. NDM Jenner Institute. £40,200
  • Developing small molecule inhibitors for a rare childhood seizure disorder: Yue, Wyatt. NDM, Structural Genomics Consortium. £42,036
  • Harnessing the properties of a small compound to improve the efficiency of reprogramming dendritic cells to pluripotency: Fairchild, Paul. Pathology Dunn School. £42,207
  • Deep Brain Stimulation for Multiple System Atrophy. Green, Alex. Surgical Sciences. £70,662
  • Structure-guided design of FAM83B inhibitors for triple negative breast cancer. Bullock, Alex. NDM. £15,000
  • MICA: Reprogramming tumor immunity by targeting tenascin-C: Kim Midwood; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences; £65,569
  • T-cell receptor-like antibodies targeting p53: Alison Banham; Radcliffe Department of Medicine;  £41,490
  • Polymer-DNA nanoparticles for Therapeutic Intracellular Delivery: Andrew Turberfield; Department of Physiology, Anatomy and Genetics; £22,506
  • Orthotopic colorectal cancer patient-derived xenograft models to test therapeutic manipulation ofGREM1: Simon Leedham; Nuffield Department of Medicine; £75,000
  • Structure-Guided Design of Sonic Hedgehog Morphogen Inhibitors: Christian Siebold; Nuffield Department of Medicine; £15,000
  • Proof-of-concept controlled human infection with Plasmodium vivax malaria to accelerate Phase II clinical trials of vaccine candidates: Angela Minassian; Nuffield Department of Medicine; £65,000
  • How does BCG vaccination facilitate protection against malaria? Milicic, Anita; Nuffield Department of Medicine; £42,803
  • CMV-vectored vaccines: second generation vectors with improved safety profile:  Sarah Sebastian; Nuffield Department of Medicine; £22,635
  • Development of a novel bivalent vaccine to prevent both Salmonella Typhi and Paratyphi infections: Christine Rollier; Department of Paediatrics; £45,223
  • Ultrasonic electrospray of intact complexes from vesicles and exosomes: Carol Robinson; Department of Chemistry; £33,835
  • Non-invasive estimation of pulmonary blood flow in primary pulmonary hypertension : Peter Robbins; Department of Physiology, Anatomy and Genetics; £40,674
  • New approaches to microsphere formulation for single dose prime-boost vaccine delivery: Anita Milicic; Nuffield Department of Clinical Medicine; £51,813
  • Utilising immune-dominant epitopes of limited variability to create a novel influenza vaccine: Sunetra Gupta; Department of Zoology; £50,421
  • Development of UGGT1 inhibitors as broad-spectrum antivirals: Zitzmann, Nicole. Biochemistry. £36,709.03
  • The development of pan-genotypic Hepatitis C virus vaccine generating T and B cell immunity: Barnes, Eleanor; Experimental Medicine; £25,000
  • A universal H1N1 influenza vaccine using an epitope of limited variability: Gupta, Sunetra; Zoology; £71,729
  • A flexible and scalable platform for creating novel medicinal macrocycles: Naismith, James; Structural Biology; £75,000
  • Pre-clinical development of therapeutic cross-reactive monoclonal antibodies to Ebola viruses: Rijal, Pramila; RDM; £62,000
  • Structure based beta-Lactamase resistant transpeptidase inhibitors to address antibiotic resistance: Schofield, Christopher; Chemistry; £31,591
  • Polymeric-DNA nanoparticles: modular delivery systems for nucleic acid-based therapies: Turberfield, Andrew J.; Physics; £72,890
  • Measuring lung inhomogeneity in paediatric cystic fibrosis: Ritchie, Grant A.D.; Chemistry; £47,813
  • Universal Big DNA assembly: transition to a translatable high throughput process: O'Callaghan, Christopher; CCMP; £70,266
  • Using DNA-based diagnostics to prevent death of children with blood disorders in sub-Saharan Africa: Schuh, Annette; Oncology; £58,590
  • Using genome variation to sort extremely rare cell populations for clinical application: Frater, John; NDM Experimental Medicine; £59,529
  • Antibody-mediated oligonucleotide delivery to brain for neurodegenerative disease: Hammond, Suzan; Paediatrics; £74,762
  • CAT&MAUS: simultaneous imaging and analysis of joint motion for clinical assessment: Mellon, Stephen; NDORMS; £70,817
  • GAPDH and extracellular vesicles: biological nanoparticles for therapy of neurodegenerative diseases: Dar, Ghulam; Paediatrics; £74,762
  • Proteomic biomarkers in IBD: Adams, Alexander; NDM Experimental Medicine; £68,400